215 related articles for article (PubMed ID: 32394430)
1. Combined Pediatric and Adult Trials Submitted to the US Food and Drug Administration 2012-2018.
Tanaudommongkon I; John Miyagi S; Green DJ; Burnham JM; van den Anker JN; Park K; Wu J; McCune SK; Yao L; Burckart GJ
Clin Pharmacol Ther; 2020 Nov; 108(5):1018-1025. PubMed ID: 32394430
[TBL] [Abstract][Full Text] [Related]
2. Pediatric drug information available at the time of new drug approvals: A cross-sectional analysis.
Hudgins JD; Bacho MA; Olsen KL; Bourgeois FT
Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):161-167. PubMed ID: 29148107
[TBL] [Abstract][Full Text] [Related]
3. Review of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act: What can the obstetric community learn from the pediatric experience?
Ren Z; Zajicek A
Semin Perinatol; 2015 Nov; 39(7):530-1. PubMed ID: 26455383
[TBL] [Abstract][Full Text] [Related]
4. A review of the experience with pediatric written requests issued for oncology drug products.
Akalu AY; Meng X; Reaman GH; Ma L; Yuan W; Ye J
Pediatr Blood Cancer; 2021 Feb; 68(2):e28828. PubMed ID: 33245181
[TBL] [Abstract][Full Text] [Related]
5. Timing of Pediatric Drug Approval and Clinical Evidence Submitted to Regulatory Authorities: International Comparison Among Japan, the United States, and the European Union.
Hirota S; Yamaguchi T
Clin Pharmacol Ther; 2020 Nov; 108(5):985-994. PubMed ID: 31869436
[TBL] [Abstract][Full Text] [Related]
6. Drug labeling changes and pediatric hematology/oncology prescribing: Measuring the impact of U.S. legislation.
Benning TJ; Shah ND; Inselman JW; Van Houten HK; Ross JS; Wyatt KD
Clin Trials; 2021 Dec; 18(6):732-740. PubMed ID: 34269090
[TBL] [Abstract][Full Text] [Related]
7. Dermatology Drugs for Children-U.S. Food and Drug Administration Perspective.
Epps RE
Dermatol Clin; 2022 Jul; 40(3):289-296. PubMed ID: 35750412
[TBL] [Abstract][Full Text] [Related]
8. Inclusion of Infants and Neonates in Pediatric Orphan Product Approvals.
Park K; Virparia R; Green DJ; Epps C; Wharton GT; McCune SK; Burckart GJ
Clin Pharmacol Ther; 2021 Oct; 110(4):997-1003. PubMed ID: 34028811
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the Impact of Mandated Postmarketing Pediatric-Focused Safety Reviews on Safety-Related Regulatory Actions 2013-2019.
Mohamoud M; Cheng C; Ryan D; Kim I; Wu E; Muñoz M; Kortepeter C; Pinnow E; Dal Pan G
Clin Pharmacol Ther; 2023 Jun; 113(6):1368-1377. PubMed ID: 37021630
[TBL] [Abstract][Full Text] [Related]
10. Duration of Pediatric Clinical Trials Submitted to the US Food and Drug Administration.
Zimmerman KO; Smith PB; McMahon AW; Temeck J; Avant D; Murphy D; McCune S
JAMA Pediatr; 2019 Jan; 173(1):60-67. PubMed ID: 30452504
[TBL] [Abstract][Full Text] [Related]
11. Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act.
Hwang TJ; Orenstein L; Kesselheim AS; Bourgeois FT
JAMA Pediatr; 2019 Jan; 173(1):68-74. PubMed ID: 30452498
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of FDA Labeling Changes Related to PREA Safety-Waivers.
Krastein J; Pica-Branco D; Bacho MA; Mulugeta Y; Maynard JW; Alexander JJ; Yao L; Hausman ED
Ther Innov Regul Sci; 2023 Sep; 57(5):1099-1103. PubMed ID: 37389793
[TBL] [Abstract][Full Text] [Related]
13. Pediatric Antibacterial and Antifungal Trials From 2007 to 2017.
Thaden JT; Chiswell K; Jaffe I; Bergin SP; Yang WE; Romaine A; Roberts J; Nambiar S; Farley J; Benjamin DK; Smith PB; Tsalik EL
Pediatrics; 2018 Sep; 142(3):. PubMed ID: 30158197
[TBL] [Abstract][Full Text] [Related]
14. Clinical trial considerations for pediatric cancer drug development.
Cooner F; Ye J; Reaman G
J Biopharm Stat; 2023 Nov; 33(6):859-874. PubMed ID: 36749066
[TBL] [Abstract][Full Text] [Related]
15. Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007.
Momper JD; Mulugeta Y; Green DJ; Karesh A; Krudys KM; Sachs HC; Yao LP; Burckart GJ
JAMA Pediatr; 2013 Oct; 167(10):926-32. PubMed ID: 23921678
[TBL] [Abstract][Full Text] [Related]
16. Patient-Reported Outcomes Labeling for Products Approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010-2014).
Gnanasakthy A; DeMuro C; Clark M; Haydysch E; Ma E; Bonthapally V
J Clin Oncol; 2016 Jun; 34(16):1928-34. PubMed ID: 27069082
[TBL] [Abstract][Full Text] [Related]
17. Impact of pediatric exclusivity on drug labeling and demonstrations of efficacy.
Wharton GT; Murphy MD; Avant D; Goldsmith JV; Chai G; Rodriguez WJ; Eisenstein EL
Pediatrics; 2014 Aug; 134(2):e512-8. PubMed ID: 25022732
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: systematic review.
Wang B; Kesselheim AS
BMJ; 2015 Sep; 351():h4679. PubMed ID: 26400844
[TBL] [Abstract][Full Text] [Related]
19. Incentivizing Orphan Product Development: United States Food and Drug Administration Orphan Incentive Programs.
Le TT
Adv Exp Med Biol; 2017; 1031():183-196. PubMed ID: 29214572
[TBL] [Abstract][Full Text] [Related]
20. What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis.
Thorat C; Xu K; Freeman SN; Bonnel RA; Joseph F; Phillips MI; Imoisili MA
Pediatrics; 2012 Mar; 129(3):516-21. PubMed ID: 22371464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
